about
Metabolic and immunological consequences of vitamin D deficiency in obese children.Candida spp. and gingivitis in children with nephrotic syndrome or type 1 diabetes.Association between metabolic disturbances and G-174C polymorphism of interleukin-6 gene in obese children.Regulatory T Cells in Obesity.Brown Adipose Tissue and Browning Agents: Irisin and FGF21 in the Development of Obesity in Children and Adolescents.High incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes among Polish children aged 10-12 and under 5 years of age: A multicenter study.Adrenal abscess in a 3-week-old neonate - a case report.Cardiovascular Risk Factors in Obese Children and Adolescents.Nutrition and Immune System in Children with Simple Obesity.Epidemiology of type 1 diabetes in Polish children: A multicentre cohort study.Carotid Intima-Media Thickness and Metabolic Syndrome Components in Obese Children and Adolescents.Functional TSH receptor antibodies in children with autoimmune thyroid diseases.Association Between Vitamin D and Carboxy-Terminal Cross-Linked Telopeptide of Type I Collagen in Children During Growth Hormone Replacement Therapy.The Diagnostics of Human Steroid Hormone Disorders.Thyroid Autoimmunity in Girls with Turner Syndrome.Influence of sublingual immunotherapy on the expression of Mac-1 integrin in neutrophils from asthmatic children.Thyroid Function in Obese Children and Adolescents and Its Association with Anthropometric and Metabolic Parameters.Association of adiponectin gene G276T polymorphism with atherogenic indicators in obese children.Lymphocytes sensitivity to Fas stimulation in healthy and asthmatic children.The relationship between alkaline phosphatase and bone alkaline phosphatase activity and the growth hormone/insulin-like growth factor-1 axis and vitamin D status in children with growth hormone deficiency.Factors associated with preservation of C-peptide levels at the diagnosis of type 1 diabetes.The pre-treatment characteristics and evaluation of the effects of recombinant human growth hormone therapy in children with growth hormone deficiency and celiac disease or inflammatory bowel disease.Immunological Characteristics of Children with Hashimoto's Autoimmune ThyroiditisOsteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone DeficiencyTreatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experienceGender-Dependent Growth and Insulin-Like Growth Factor-1 Responses to Growth Hormone Therapy in Prepubertal Growth Hormone-Deficient ChildrenRelationship Between 25(OH)D and IGF-I in Children and Adolescents with Growth Hormone DeficiencySeasonal Variation in Month of Diagnosis of Polish Children with Type 1 Diabetes - A Multicenter StudyBody Mass Disorders in Healthy Short Children and in Children with Growth Hormone DeficiencyThe associations between the growth hormone/insulin-like growth factor-1 axis, adiponectin, resistin and metabolic profile in children with growth hormone deficiency before and during growth hormone treatmentEvaluation of glucose metabolism in children with growth hormone deficiency during long-term growth hormone treatment
P50
Q34443549-6279C7F7-9153-4671-9E0A-AB118721B01FQ35588289-26586EDC-3757-4D78-92C1-AE6CE714EF1EQ36464066-593AD1E2-4F14-4E8D-9EE1-9102F08643F8Q38506975-5E0CCE86-85C2-4740-979E-0365F8F7123DQ38506982-85370C6B-61E4-447D-A477-D03B92A92FA8Q39303513-084E6CBE-61AF-4263-90E4-6B37D91C700EQ40819530-A0DDF67E-4731-41B7-AA58-3EE7C025FCE5Q41240382-FE90C8D4-DA0F-45AC-89A5-005EBF56CA7CQ41487576-C1123146-4D45-44A7-AAA9-BB4DAB6DEEECQ47587189-DB8F25B0-3F55-4B8F-9FD1-A804758691CFQ48657391-0B1C8565-9508-4C83-BBE0-398341D2100FQ49668161-2EE4F37A-1A5A-4AB5-94FA-27A4F09725D4Q49941764-8C466257-B958-4D44-81FA-3DD5BA3DB13BQ50430647-A6014320-D66E-4C93-8840-A88325442F3FQ50440806-6841A5D6-FD70-4A78-B996-03E8DFAFEC64Q50793439-57728129-F58B-4AD7-85D5-38DE07AE1FE8Q51286018-3CE98791-1B02-459B-9DB0-C3B6C1B395DAQ51353497-933D8FED-E919-4A82-8C13-CCFAFBD47689Q51943627-4C006389-BFD4-4BFB-B559-363784AB6D8FQ52323498-ADF71002-AB0E-41F0-9865-A6D37359CE95Q52716427-5608A17A-1240-4518-9537-7FE49A4C9879Q54939588-B3E09710-7816-4DAE-9318-FA35C8CE7DEAQ56896311-5EBFBD21-1CD4-476F-B130-9409F073ADB1Q56977860-5D4D0ADF-9AF2-4014-933D-C589C96AEB7BQ57796816-C2C6B5F8-888A-47A5-B34B-88A36B5BDE7AQ58585766-A4D2EFC8-C9F4-4DA0-A584-9CB3EABB8199Q87480236-BC07D47E-352C-4A2F-ACB4-01E9141AFEABQ87967649-3673C98C-F358-48F9-9ED5-4D9ABEF5CFC7Q88374242-5942545E-F852-441D-8543-194BE38E5902Q89139147-E2253CE1-5859-4408-9B6F-182D9FC0D603Q89447105-B50932FF-C7A6-4B66-9009-F921AF7525E3
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-8914-7815
@en
name
Beata Pyrzak
@ast
Beata Pyrzak
@en
Beata Pyrzak
@es
Beata Pyrzak
@nl
Beata Pyrżak
@ca
Beata Pyrżak
@cs
Beata Pyrżak
@gl
Beata Pyrżak
@hr
Beata Pyrżak
@hsb
Beata Pyrżak
@it
type
label
Beata Pyrzak
@ast
Beata Pyrzak
@en
Beata Pyrzak
@es
Beata Pyrzak
@nl
Beata Pyrżak
@ca
Beata Pyrżak
@cs
Beata Pyrżak
@gl
Beata Pyrżak
@hr
Beata Pyrżak
@hsb
Beata Pyrżak
@it
prefLabel
Beata Pyrzak
@ast
Beata Pyrzak
@en
Beata Pyrzak
@es
Beata Pyrzak
@nl
Beata Pyrżak
@ca
Beata Pyrżak
@cs
Beata Pyrżak
@gl
Beata Pyrżak
@hr
Beata Pyrżak
@hsb
Beata Pyrżak
@it
P106
P1153
6508104124
P1412
P1559
Beata Pyrżak
@pl
P21
P27
P31
P3124
P496
0000-0001-8914-7815